In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Healthcare Services (HCSG – Research Report) and ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research ...

Patrick Trucchio; Analyst; H.C. Wainwright. Mayank Mamtani; Analyst; B. Riley Securities. I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations of Arrowhead.

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

Mayank Mamtani is an analyst at B. Riley Securities. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected ...

Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at $38.00. Discover outperforming stocks and ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Agenus (AGEN – Research Report) today and set a price target of $11.00. Discover outperforming stocks and invest smarter with ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of $20.00. The company’s shares closed yesterday at $7.00.

Failed to fetch dynamically imported module: https://au.finance.yahoo.com/assets/_app/immutable/nodes/105.DOJoPAWP.js ...